文献速递临床试验与 GCP

多囊卵巢综合征女性体外受精前补充维生素D:多中心、双盲、安慰剂对照、随机临床试验

Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome: multicentre, double blind, placebo controlled, randomised clinical trial.
PubMed 文献 · BMJ · 2026-02-17

这项多中心、双盲、安慰剂对照随机临床试验纳入876例接受体外受精的多囊卵巢综合征女性,按1:1随机接受维生素D 4000 IU/天或安慰剂至触发日(最长90天)。维生素D组触发日血清25-羟基维生素D水平显著高于安慰剂组(32.3±11.2 vs 18.2±7.6 ng/mL,校正均数差13.6,95%CI 10.9至16.3),但首次胚胎移植后活产率两组无显著差异(52.0% vs 50.2%,校正RR 1.03,95%CI 0.91至1.18)。

要点

  • 维生素D 4000 IU/天至触发日可显著提高多囊卵巢综合征患者触发日血清25-羟基维生素D水平。
  • 维生素D组与安慰剂组首次胚胎移植后活产率无显著差异(52.0% vs 50.2%,校正RR 1.03,95%CI 0.91至1.18)。
  • 重度卵巢过度刺激综合征在维生素D组和安慰剂组分别发生3例和6例(校正风险差-0.7%,95%CI -2.0%至0.6%)。

核心结论

  • 虽然维生素D补充(4000 IU/天)最长90天可提高血清25-羟基维生素D水平,但并未转化为多囊卵巢综合征患者首次移植后活产率的改善。

研究设计与样本

  • 多中心、双盲、安慰剂对照、随机临床试验,在中国24个生殖中心开展。
  • 共876例接受体外受精的多囊卵巢综合征参与者按1:1随机接受维生素D 4000 IU/天或安慰剂,至触发日最长90天。
  • 865例纳入改良意向性治疗分析,其中维生素D组435例、安慰剂组430例。

主要发现

  • 基线平均血清25-羟基维生素D水平在维生素D组和安慰剂组分别为16.5±7.2和16.1±6.7 ng/mL。
  • 触发日血清25-羟基维生素D水平维生素D组显著高于安慰剂组(32.3±11.2 vs 18.2±7.6 ng/mL,校正均数差13.6,95%CI 10.9至16.3)。
  • 维生素D组活产226例(52.0%),安慰剂组216例(50.2%),校正RR 1.03(95%CI 0.91至1.18)。
  • 重度卵巢过度刺激综合征在维生素D组和安慰剂组分别发生3例和6例(校正风险差-0.7%,95%CI -2.0%至0.6%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether vitamin D supplementation improves live birth rates in women with polycystic ovary syndrome undergoing in vitro fertilisation. DESIGN: Multicentre, double blind, placebo controlled, randomised clinical trial. SETTING: 24 fertility centres in China. PARTICIPANTS: 876 participants with polycystic ovary syndrome undergoing in vitro fertilisation. INTERVENTIONS: Participants were randomised (1:1) to receive vitamin D 4000 IU/day or placebo before in vitro fertilisation for up to 90 days until the trigger day. MAIN OUTCOMES MEASURES: The primary outcome was live birth after the first embryo transfer. Secondary outcomes included serum 25-hydroxyvitamin D (25-OHD) levels on trigger day, pregnancy outcomes, fertility outcomes, and adverse events including severe ovarian hyperstimulation syndrome. RESULTS: Of 876 participants randomised, 865 were included in the modified intention-to-treat analysis, with 435 in the vitamin D group and 430 in the placebo group. Baseline mean serum 25-OHD levels were 16.5±7.2 and 16.1±6.7 ng/mL in the vitamin D and placebo groups, respectively. On the day of triggering, the serum 25-OHD level was significantly higher in the vitamin D group than in the placebo group (32.3±11.2 v 18.2±7.6 ng/mL, adjusted mean difference 13.6, 95% confidence interval 10.9 to 16.3). 226 (52.0%) live births occurred in the vitamin D group and 216 (50.2%) in the placebo group (adjusted risk ratio 1.03, 95% confidence interval 0.91 to 1.18). Severe ovarian hyperstimulation syndrome occurred in three and six participants in the vitamin D and placebo groups, respectively (adjusted risk difference -0.7%, 95% confidence interval -2.0% to 0.6%). CONCLUSIONS: Although vitamin D supplementation (4000 IU/day) for up to 90 days increases serum 25-OHD levels, this does not translate to improved live birth rates after the first transfer for patients with polycystic ovary syndrome. TRIAL REGISTRATION: ClinicalTrials.gov NCT04082650.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Hu KL, Liao T, Wu Q, et al. Vitamin D supplementation before in vitro fertilisation in women with polycystic ovary syndrome: multicentre, double blind, placebo controlled, randomised clinical trial. BMJ. 2026. PMID: 41702641. doi:10.1136/bmj-2025-087438

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。